In addition to the uncertainty of rpoB mutations in association with RIF resistance, there is a similar issue for rrs with resistance to injectable drugs. This realization will likely extend to mutations associated with other classes of drugs as molecular assays for mutation detection are more widely implemented. The sequence information provided by PSQ or other sequence-based assays and the evolving knowledge of the MIC range associated with each mutation allow users to interpret and to report mutations properly.